Company / Accounts Receivable
Tarsus Pharmaceuticals, Inc. Accounts Receivable History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$85.1M
FY2025
5-year range
$16.6M / $85.1M
FY2023-FY2025
Trend
+81.9%
vs FY2024
Sector context
#59 of 113
Health Care
What the data says
At $85M, Tarsus Pharmaceuticals, Inc.'s accounts receivable ranks #59 of 113 in the Health Care sector. Improved from $17M to $85M over the past 2 years.
Based on SEC 10-K filings.
$85M in FY2025.
Improved from $17M to $85M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#59 of 113 in Health CareTop 52% of 113This company $85.1M Sector average $1.1B
▼
-92.5% below sector average
Key checks
Key Insights
- In FY2025, accounts receivable increased 81.9% year-over-year.
- Ranks #59 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $85.1M | +81.9% |
| FY2024 | $46.8M | +181.3% |
| FY2023 | $16.6M | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026